Fresenius Medical Care presents a mixed fundamental picture: stable dialysis volumes and modest gross margin expansion to 27.0% in 2026Q2 are offset by persistent operating margin compression (9.6%) driven by labor cost inflation. The company generates robust ...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth remains subdued at 1.4% YoY in 2026Q2, while gross margin improved to 27.0% but operating margin contracted to 9.6% due to elevated SG&A costs.
Wall Street analysts have a consensus twelve-month stock price forecast of $28.00 for Fresenius Medical Care, indicating potential upside.
Fresenius Medical Care is presented as a compelling deep-value, contrarian investment for long-term investors, especially after a significant share price decline.
The company has shown 38% growth in 2025 adjusted earnings per share, with a stable profit outlook for 2026.
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 3, 2026 | $0.66+7.1% vs $0.62 | $5.6B+2.2% vs $5.5B |
Q2 2026 May 5, 2026 | $0.53-10.2% vs $0.59 | $5.4B-0.1% vs $5.4B |
Q1 2026 Feb 24, 2026 | $0.83+28.3% vs $0.65 | $6.0B+5.3% vs $5.7B |
Q4 2025 Nov 4, 2025 | $0.64+8.5% vs $0.59 | $5.7B+19.2% vs $4.8B |
Tidal Investments LLC grew its stake in shares of Fresenius Medical Care AG and Co. KGaA (NYSE: FMS) by 96.0% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 99,790 shares of the company's stock after acquiring an additional
Fresenius Medical is scaling its 5008X rollout across U.S. clinics, creating growth potential despite volume, reimbursement and rollout-cost pressures.
Fresenius Medical's improving profitability, 5008X rollout and value-based care gains offer support despite volume and reimbursement risks.
Fresenius Medical Care AG and Co. KGaA (NYSE: FMS - Get Free Report) shares passed above its two hundred day moving average during trading on Thursday. The stock has a two hundred day moving average of $23.13 and traded as high as $23.92. Fresenius Medical Care AG and Co. KGaA shares last traded at $23.43,
Benchmark FMS against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Fresenius Medical Care AG & Co. KGaA (FMS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $22.50 | $12.09B | 11.68 | 1.51% | 4.98% | 6.51% | 3.55% | |
| $183.72 | $11.79B | 19.32 | 6.46% | 6.05% | 70.42% | — | |
| $30.46 | $275.39M | 15.54 | 33.46% | 18.47% | 11.57% | — | |
| $60.97 | $2.02B | -6.27 | -43.89% | -287.84% | -37.99% | — | |
| $23.68 | $12.23B | -13.53 | 5.72% | -9.27% | -16.67% | — | |
| $5.96 | $3.32M | -3.64 | — | — | — | — |
Fresenius Medical Care AG & Co. KGaA (FMS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when FMS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Fresenius Medical Care AG & Co. KGaA (FMS) stock FAQ — growth, dividends, profitability & financials explained
Fresenius Medical Care AG & Co. KGaA (FMS) reported $19.43B in revenue for fiscal year 2025. This represents a 550% increase from $2.99B in 1998.
Fresenius Medical Care AG & Co. KGaA (FMS) grew revenue by 1.5% over the past year. Growth has been modest.
Yes, Fresenius Medical Care AG & Co. KGaA (FMS) is profitable, generating $937.8M in net income for fiscal year 2025 (5.0% net margin).
Yes, Fresenius Medical Care AG & Co. KGaA (FMS) pays a dividend with a yield of 3.55%. This makes it attractive for income-focused investors.
Fresenius Medical Care AG & Co. KGaA (FMS) has a return on equity (ROE) of 6.5%. This is below average, suggesting room for improvement.
Fresenius Medical Care AG & Co. KGaA (FMS) generated $1.77B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
